Lantern Pharma Wins EU Patent for AI-Developed Cancer Therapy
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage oncology company leveraging its proprietary RADR® artificial intelligence (AI) platform to accelerate drug discovery, today announced that the European...